EUR-Lex Acces la dreptul Uniunii Europene
Acest document este un extras de pe site-ul EUR-Lex
Document 62018TA0377
Case T-377/18: Judgment of the General Court of 28 June 2019 — Intercept Pharma and Intercept Pharmaceuticals v EMA (Access to documents — Regulation (EC) No 1049/2001 — Documents held by EMA containing information submitted by the applicants in the context of the marketing authorisation for the medicinal product Ocaliva — Decision to grant a third party access to a document — Exception relating to the protection of court proceedings)
Case T-377/18: Judgment of the General Court of 28 June 2019 — Intercept Pharma and Intercept Pharmaceuticals v EMA (Access to documents — Regulation (EC) No 1049/2001 — Documents held by EMA containing information submitted by the applicants in the context of the marketing authorisation for the medicinal product Ocaliva — Decision to grant a third party access to a document — Exception relating to the protection of court proceedings)
Case T-377/18: Judgment of the General Court of 28 June 2019 — Intercept Pharma and Intercept Pharmaceuticals v EMA (Access to documents — Regulation (EC) No 1049/2001 — Documents held by EMA containing information submitted by the applicants in the context of the marketing authorisation for the medicinal product Ocaliva — Decision to grant a third party access to a document — Exception relating to the protection of court proceedings)
OJ C 288, 26.8.2019, p. 51-51
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
26.8.2019 |
EN |
Official Journal of the European Union |
C 288/51 |
Judgment of the General Court of 28 June 2019 — Intercept Pharma and Intercept Pharmaceuticals v EMA
(Case T-377/18) (1)
(Access to documents - Regulation (EC) No 1049/2001 - Documents held by EMA containing information submitted by the applicants in the context of the marketing authorisation for the medicinal product Ocaliva - Decision to grant a third party access to a document - Exception relating to the protection of court proceedings)
(2019/C 288/64)
Language of the case: English
Parties
Applicants: Intercept Pharma Ltd (Bristol, United Kingdom) and Intercept Pharmaceuticals, Inc., (New York, New York, United States), (represented by: L. Tsang, J. Mulryne, E. Amos and H. Kerr-Peterson, Solicitors, and F. Campbell, Barrister)
Defendant: European Medicines Agency (represented by: initially by S. Marino, S. Drosos, A. Rusanov and T. Jabłoński, and subsequently by S. Marino, S. Drosos, T. Jabłoński, R. Pita and G. Gavriilidou, Agents)
Re:
Action under Article 263 TFEU for the annulment of EMA decision ASK-40399 of 15 May 2018, granting to a third party, pursuant to Regulation (EC) No 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents (OJ 2001 L 145, p. 43), access to a document containing information submitted in the context of an application for marketing authorisation for the medicinal product Ocaliva.
Operative part of the judgment
The Court:
|
1. |
Dismisses the action; |
|
2. |
Orders Intercept Pharma Ltd and Intercept Pharmaceuticals, Inc. to pay the costs. |